CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 160 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $314,719 | -17.7% | 11,436 | +1.5% | 0.00% | 0.0% |
| Q2 2023 | $382,425 | -2.6% | 11,271 | +3.2% | 0.00% | -25.0% |
| Q1 2023 | $392,794 | -16.5% | 10,917 | +3.4% | 0.00% | -20.0% |
| Q4 2022 | $470,570 | +64.5% | 10,558 | +3.9% | 0.01% | +66.7% |
| Q3 2022 | $286,000 | +4.8% | 10,164 | +0.5% | 0.00% | 0.0% |
| Q2 2022 | $273,000 | -20.6% | 10,117 | +0.3% | 0.00% | 0.0% |
| Q1 2022 | $344,000 | -11.1% | 10,091 | +0.8% | 0.00% | 0.0% |
| Q4 2021 | $387,000 | -32.1% | 10,008 | -5.1% | 0.00% | -40.0% |
| Q3 2021 | $570,000 | +58.3% | 10,550 | -1.9% | 0.01% | +66.7% |
| Q2 2021 | $360,000 | +51.9% | 10,755 | -6.6% | 0.00% | +50.0% |
| Q1 2021 | $237,000 | +19.1% | 11,518 | +1.5% | 0.00% | 0.0% |
| Q4 2020 | $199,000 | – | 11,347 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |